论文部分内容阅读
目的:探讨经皮冠脉介入治疗(Percutaneous coronary intervention,PCI)后不同时间双联抗血小板治疗的有效性和安全性。方法:选取接受PCI治疗的患者878例,按照双联抗血小板的治疗时间分为<3个月组、3～6个月组、7～12个月组和>12个月组,分析其心血管不良事件和药物不良反应的发生情况。结果:全部患者随访1～4年,各组患者的心源性死亡的发生率差异无统计学意义(P>0.05),心绞痛、心力衰竭、心肌梗死和再次血运重建的发生情况差异均有统计学意义(P<0.05),>6个月组的发生率明显更低,但7～12个月组和>12个月两组组间相比,差异无统计学意义(P>0.05)。患者轻微出血和严重出血事件的发生率,各组之间相比,差异均无统计学意义(P>0.05)。结论:PCI术后双联抗血小板治疗>6个月能降低患者心血管不良事件的发生率,且不会明显增加出血事件发生率。
Objective: To investigate the efficacy and safety of dual antiplatelet therapy at different times after percutaneous coronary intervention (PCI). Methods: A total of 878 patients undergoing PCI were enrolled in this study. Patients were divided into 3 months, 3 to 6 months, 7 to 12 months, and> 12 months according to the duration of dual antiplatelet therapy. Vascular adverse events and adverse drug reactions occurred. Results: All patients were followed up for 1 to 4 years. There was no significant difference in the incidence of cardiac death between the two groups (P> 0.05). There were significant differences in the incidence of angina pectoris, heart failure, myocardial infarction and revascularization (P <0.05), and the incidence of> 6 months group was significantly lower, but there was no significant difference between the 7 ~ 12 months group and the> 12 months group (P> 0.05) . There was no significant difference between the groups in the incidence of minor bleeding and severe bleeding (P> 0.05). Conclusions: Dual antiplatelet therapy for 6 months after PCI reduces the incidence of cardiovascular adverse events and does not significantly increase the incidence of bleeding events.